HEALTHApr 28 · 17:23 UTCBLOOMBERGAvalon Pernell, Angel Adegbesan

Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death

Cancer drug developer Erasca's stock plummeted 55% following a patient death linked to its clinical trials. The significant drop highlights investor concerns over drug safety and regulatory risks.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

ErascaorganizationCancer DrugtopicPatient Deathtopic

Spot something wrong with this article?Report a problem →

Forward this